Clarity Pharmaceuticals Hits Participant Target in Phase 3 Prostate Cancer Diagnostic Agent Trial

MT Newswires Live

Mar 10

Clarity Pharmaceuticals (ASX:CU6) said it achieved the target number of participants for its phase 3 Amplify trial for copper-64-SAR-bisPSMA positron emission tomography in participants with rising or detectable prostate-specific antigen (PSA) after initial definitive treatment, according to a Tuesday ASX filing.

The study, which will enroll 220 participants, seeks to investigate the diagnostic ability of copper-64-SAR-bisPSMA positron emission tomography/computed tomography to detect the recurrence of prostate cancer in men with PSA levels above 0.2 nanograms per milliliter.

Consenting of new patients stopped at all sites pending the completion of the remaining screening assessments and confirmation of final enrollment numbers, the filing said.

The company's shares rose past 2% in recent trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2618601573"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618601573\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618601573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618601573","market":"hk","top_or_hot":-1,"title":"Clarity Pharmaceuticals Hits Participant Target in Phase 3 Prostate Cancer Diagnostic Agent Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) said it achieved the target number of participants for its phase 3 Amplify trial for copper-64-SAR-bisPSMA positron emission tomography in participants with rising or detectable prostate-specific antigen (PSA) after initial definitive treatment, according to a Tuesday ASX filing.</p><p>The study, which will enroll 220 participants, seeks to investigate the diagnostic ability of copper-64-SAR-bisPSMA positron emission tomography/computed tomography to detect the recurrence of prostate cancer in men with PSA levels above 0.2 nanograms per milliliter.</p><p>Consenting of new patients stopped at all sites pending the completion of the remaining screening assessments and confirmation of final enrollment numbers, the filing said.</p><p>The company's shares rose past 2% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Pharmaceuticals Hits Participant Target in Phase 3 Prostate Cancer Diagnostic Agent Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Pharmaceuticals Hits Participant Target in Phase 3 Prostate Cancer Diagnostic Agent Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-10 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> (ASX:CU6) said it achieved the target number of participants for its phase 3 Amplify trial for copper-64-SAR-bisPSMA positron emission tomography in participants with rising or detectable prostate-specific antigen (PSA) after initial definitive treatment, according to a Tuesday ASX filing.</p><p>The study, which will enroll 220 participants, seeks to investigate the diagnostic ability of copper-64-SAR-bisPSMA positron emission tomography/computed tomography to detect the recurrence of prostate cancer in men with PSA levels above 0.2 nanograms per milliliter.</p><p>Consenting of new patients stopped at all sites pending the completion of the remaining screening assessments and confirmation of final enrollment numbers, the filing said.</p><p>The company's shares rose past 2% in recent trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4217","symbol_name":"自存仓储房地产信托","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618601573","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618601573","pubTimestamp":1773106735,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clarity Pharmaceuticals (ASX:CU6) said it achieved the target number of participants for its phase 3 Amplify trial for copper-64-SAR-bisPSMA positron emission tomography in participants with rising or","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4217":"自存仓储房地产信托","BK7096":"制药","BK4588":"碎股","CU6.AU":"CLARITY PHARMACEUTICALS LTD","PSA":"公共存储公司","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4585":"ETF&股票定投概念","BK4084":"特种房地产投资信托"},"translate_title":"Clarity Pharmaceuticals在前列腺癌诊断剂3期试验中达到参与者目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":1,"PSA":1},"content_text":"Clarity Pharmaceuticals (ASX:CU6) said it achieved the target number of participants for its phase 3 Amplify trial for copper-64-SAR-bisPSMA positron emission tomography in participants with rising or detectable prostate-specific antigen (PSA) after initial definitive treatment, according to a Tuesday ASX filing.The study, which will enroll 220 participants, seeks to investigate the diagnostic ability of copper-64-SAR-bisPSMA positron emission tomography/computed tomography to detect the recurrence of prostate cancer in men with PSA levels above 0.2 nanograms per milliliter.Consenting of new patients stopped at all sites pending the completion of the remaining screening assessments and confirmation of final enrollment numbers, the filing said.The company's shares rose past 2% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}